Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2026

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

38,173,887

Number of real voting rights* (excluding treasury shares**)

38,105,069

Theoretical number of voting rights* (including treasury shares**)

38,150,687

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260407652787/en/

The Median Technologies Stock at the time of publication of the news with a fall of -1,83 % to 4,56EUR on Tradegate stock exchange (02. April 2026, 22:25 Uhr).

Schreibe Deinen Kommentar